TP53 and malignant colon neoplasm: In conclusion, our findings suggested the ability of lobeline to inhibit colon cancer through modulation of macrophage polarization via the MAPK14/p53/Slurp1 signaling pathway (Figure 8J) and demonstrate that lobeline and PD‐1 blockade synergistically inhibit tumor progression.